Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Zonder, J. A. et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120, 552–559 (2012).
Wolf, J. L. et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma. 53, 1820–1823 (2012).
Blackwell, K. L. et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20, 1026–1031 (2009).
Ocaña, A., Amir, E., Vera, F., Eisenhauer, E. A. & Tannock, I. F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J. Clin. Oncol. 29, 254–256 (2011).
Sledge, G. W. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21, 588–592 (2003).
Gyawali, B. & Prasad, V. Same data; different interpretations. J. Clin. Oncol. 34, 3729–3732 (2016).
Inman, S. ODAC votes against panobinostat in multiple myeloma. OncLive http://www.onclive.com/web-exclusives/odac-votes-against-panobinostat-in-multiple-myeloma (2014).
Dimopoulos, M. et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 14, 1129–1140 (2013).
Orlowski, R. Z. et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer 122, 2050–2056 (2016).
The authors declare no competing financial interests.
About this article
Cite this article
Gyawali, B., Prasad, V. Drugs that lack single-agent activity: are they worth pursuing in combination?. Nat Rev Clin Oncol 14, 193–194 (2017). https://doi.org/10.1038/nrclinonc.2017.27
Nature Reviews Clinical Oncology (2020)
Nature Reviews Clinical Oncology (2018)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond